GHK-Cu and melasma: what the science says about copper peptides

What did @briiifreakingana actually say?

The caption does the heavy lifting here. The creator says GHK-Cu has helped their melasma "tremendously" and that they've been "pining" (pinning, presumably, as in injecting or applying topically) GHK-Cu and TB-500 together for about a month. The transcript itself is song lyrics, so the actual spoken claims live in the caption and visual content. That matters, because a before-and-after skin comparison with no controlled conditions is not evidence of causation. It's a testimonial, and testimonials have a well-documented reliability problem in dermatology.

The creator also tags "Musely," a telehealth platform that prescribes compounded topicals for melasma, suggesting they may be using multiple interventions simultaneously. If they're using a prescription hyperpigmentation formula alongside peptides, attributing improvement to GHK-Cu alone is not scientifically defensible. That's a confounding variable problem, not a minor footnote.

Does the science back this up?

The honest answer is: partially, in lab settings, with significant caveats. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has real research behind it, just not for melasma specifically. Studies like Pickart et al. (2015, Journal of Aging Science) document GHK-Cu's role in skin remodeling, collagen synthesis, and antioxidant activity. Separately, some copper peptide research suggests modulation of melanocyte activity, but the pathway is complicated.

Here's the problem: melanogenesis inhibition by GHK-Cu is not well-established in human clinical trials for melasma. A 2018 review in the International Journal of Molecular Sciences noted copper peptides show promise for wound healing and anti-aging applications, but melasma is a hormonally driven pigmentation disorder with deep dermal involvement. The peer-reviewed evidence for GHK-Cu as a standalone melasma treatment is essentially nonexistent at this point. Animal models and in vitro data are not the same as randomized controlled trials in humans with melasma.

What did they get wrong (or right)?

What they got right: GHK-Cu is a legitimately studied peptide with a reasonable safety profile in topical and low-dose injectable applications. It's not snake oil. The enthusiasm for its skin-related effects is not entirely unfounded, and the broader peptide community has outpaced regulatory interest in some genuinely interesting compounds.

What they got wrong, or at least dangerously oversimplified: saying GHK-Cu helped melasma "tremendously" after one month, while also using Musely (which commonly prescribes compounded hydroquinone, tretinoin, or azelaic acid formulas), is a classic attribution error. Melasma also fluctuates with sun exposure, hormonal cycles, and stress. One month of data with multiple simultaneous interventions and no controls tells us almost nothing about which variable is responsible for any visible improvement.

Stacking GHK-Cu with TB-500 is also worth flagging. TB-500 (Thymosin Beta-4) is used for tissue repair and has its own emerging literature, but combining peptides without clinical guidance introduces unpredictable interaction variables. Neither compound is FDA-approved, and both are typically obtained through compounding pharmacies or research chemical suppliers with variable quality control.

What should you actually know?

Melasma is one of the harder skin conditions to treat. Standard-of-care options, things like topical hydroquinone, tretinoin, azelaic acid, tranexamic acid, and laser therapy, have actual randomized controlled trial data behind them. Kauvar (2012, Dermatologic Surgery) and others have documented how stubborn and recurrent melasma can be even with proven treatments.

GHK-Cu is not a replacement for those. At best, it might be a complementary approach with plausible mechanisms but unproven clinical outcomes for this specific indication. Anyone seeing this video and considering peptide injections for melasma should know that the regulatory status of injectable GHK-Cu is murky, quality control across suppliers varies widely, and the evidence base for this specific use case is thin. Skin-improvement claims on TikTok backed by 30-day personal experience deserve significant skepticism, regardless of how compelling the before-and-after looks.